Posted on 02/08/2010 in Scientific Grifols has successfully expanded its business in the first half of 2010, with sales up by 3.7 per cent year-on-year despite challenging economic conditions.
The science firm saw its six-month sales total rise to 487.8 million euros (308.6 million pounds), with its main bioscience, diagnostic and hospital divisions gaining 7.3 per cent on a constant currency basis.
According to the company's financial report, the period was marked by double-digit growth in the IVIG and alumbin sales categories, as well as success in Grifols' international diversification strategy.
It has also been able to continue to implement cost-saving initiatives across all business areas as it looks to maintain its sales margins.
Grifols stated that these results, in addition to its net debt reduction progress, serve to "underscore the solid balance sheet and the group's ability to fulfil future commitments".
In June, the company agreed a deal with Progenika Biopharma to acquire global marketing rights to the Bloodchip test range, a new molecular biology product. Other news stories from 02/08/2010
Read more in the Zenopa News Archive
How this news is generated
|
